Bob Saget will host the 42nd annual “Cool Comedy — Hot Cuisine” benefit of the Scleroderma Research Foundation (SRF) on Tuesday, Dec. 10. Saget, a well-known actor and a board member of SRF, will be joined by fellow comedians Michael Che, Jim Gaffigan and John Oliver, and by other special guests, according to a press…
Read in Spanish The National Health Surveillance Agency (ANVISA), an institution attached to the Brazilian Ministry of Health, approved on Tuesday a regulation for ...
Read in Spanish A foundation formally registered at the State Office wants to help promote the research, development and legal production of natural medicines, ...
A single dose of an engineered antibody known as CD45-ADC can effectively eliminate disease-causing immune cells and ease the symptoms of scleroderma in mice, studies show. CD45-ADC is an example of Magenta Therapeutics‘ efforts to develop targeted antibody-drug conjugates (ADCs) to specifically remove disease-causing cells from the body and reset the overall immune response without…
Health Canada has approved Ofev (nintedanib) as a treatment to slow the decline of pulmonary function in people with scleroderma-associated interstitial lung disease (SSc-ILD). The approval makes Ofev, by Boehringer Ingelheim, the first treatment for people with SSc-ILD available in Canada. It follows the therapy’s recent approval in the U.S. for the same indication. “When systemic sclerosis [scleroderma] involves the lungs,…
Cardiopulmonary exercise testing (CPET), along with an algorithm that considers both lung and heart functions, can help lower the unnecessary use of right heart catheterization to determine if a scleroderma patient has pulmonary arterial hypertension, a study reports. The study, “Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic…
An advanced imaging technique, called ultra-high-frequency ultrasound (UHF-US), provides detailed information of all skin layers to better detect and characterize skin involvement in people with scleroderma, a pilot study reports. The ability of this technology to precisely measure damage in the dermis, the skin’s inner layer, may be explored in the future to quantify disease…
After almost 100 years, the country that invented the federal cannabis ban seeks to end it. A divided congress approved on Wednesday a bill ...
People with diffuse cutaneous scleroderma (dcSSc) being treated with lenabasum continue to show improvement after more than two years of the therapy, an update from a Phase 2 extension study shows. The research, “Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis…
Rare disease-themed videos glowed on a large screen before an audience of people in wheelchairs, with crutches, and bearing oxygen tanks this Nov. 9 and 10 in San Francisco. Disorder: The Rare Disease Film Festival strives to eventually host a film about every one of the nearly 7,000 rare diseases that have been discovered; on…